Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Viatris Inc.
Viatris makes and sells generic and branded medicines and biosimilars to patients and pharmacies around the world.
Viatris is a medicine company built on volume. It sells generic drugs — copies of medicines whose patents have expired — along with branded drugs and complex products like biosimilars, which are close copies of expensive biologic drugs made from living cells. Its customers are pharmacies, hospitals, and health systems in more than 165 countries, and patients ultimately pay through their prescriptions.
The business works like a giant wholesale pharmacy shelf. Viatris makes or packages thousands of different medicines, from everyday pills to injectables, and sells them under many local brand names rather than one big global label. Generics are cheap to make but earn thin margins, so the real engine is scale: making enormous quantities and spreading fixed costs across many countries. Its branded and complex products earn better margins and are the growth bet. It also runs a large contract manufacturing arm, making medicines for other companies. Viatris was created in 2020 when Mylan merged with Pfizer's off-patent drug business, Pfizer. The deal made it one of the world's largest generics makers, but it came with heavy debt. Management has since focused on paying that down, selling non-core pieces, and buying back shares — a deliberate shift toward a leaner, more profitable company. Competition is brutal: Teva, Sandoz, and many low-cost Indian and Chinese makers all fight over the same generic prescriptions, and price deflation in the U.S. is a constant pressure.
The honest picture is a company in transition. Generics volume is reliable but low-margin, so Viatris is pushing into complex generics and biosimilars where fewer rivals can compete. It pays a dividend and returns cash to shareholders, but its fate hinges on whether those higher-value products grow fast enough to offset falling prices on the commodity pills that still pay most of the bills.
Saved answer · last researched 12 Nov 2026